Csquare, the data centre infrastructure business backed by Brookfield Asset Management (BAM), made its public market debut on the New York Stock Exchange amid a choppy reception from investors. The company entered
More
The summer of 2026 has delivered two of the most anticipated health wearables in recent memory, targeting vastly different consumers and budgets. One device costs £500 and is aimed at serious athletes
More
Taylor Swift and Travis Kelce’s high-profile engagement has prompted legal experts to examine what a prenuptial agreement between the two would actually need to achieve. Swift’s estate is reportedly valued at approximately
More
The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee is set to meet on July 23 and 24 to discuss a significant regulatory question for compounders. The PCAC will evaluate whether
More
Health Insurance Coalition Launches Six-Figure Ad Campaign Against No Surprises Act Enforcement Bill
The Coalition Against Surprise Medical Billing has launched a six-figure advertising campaign urging policymakers to reject the No Surprises Act Enforcement Act. The coalition argues the legislation would reward stakeholders it accuses
More
Marks and Spencer Group PLC (LSE:MKS) could see its share price double over the medium to longer term as years of sustained investment begin to deliver returns, according to Shore Capital. Shore
More
UnitedHealth Group posted stronger-than-expected revenue results for the second quarter of CY2026, sending its stock sharply higher following the announcement. The health insurance and managed care giant has faced a turbulent period
More
The FTSE 250 index is frequently overlooked by income investors who tend to gravitate toward the larger, more established companies sitting in the FTSE 100. Many investors associate dividend income with blue-chip
More
England’s heartbreaking World Cup exit attracted a massive television audience, making it the most-watched live TV moment of 2026 so far. Around 24 million viewers tuned in to watch Argentina’s late 2-1
More
Novo Nordisk has received European Commission marketing authorization for its Wegovy pill, giving the Danish drugmaker another significant head start over rival Eli Lilly. The approval covers adults with obesity or who
More